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A B S T R A C T
Background
Heavy alcohol consumption causes alcoholic liver disease and is a causal factor of many types of liver injuries and concomitant diseases.
It is a true systemic disease that may damage the digestive tract, the nervous system, the heart and vascular system, the bone and
skeletal muscle system, and the endocrine and immune system, and can lead to cancer. Liver damage in turn, can present as multiple
alcoholic liver diseases, including fatty liver, steatohepatitis, fibrosis, alcoholic cirrhosis, and hepatocellular carcinoma, with presence
or absence of hepatitis B or C virus infection. There are three scarring types (fibrosis) that are most commonly found in alcoholic liver
disease: centrilobular scarring, pericellular fibrosis, and periportal fibrosis. When liver fibrosis progresses, alcoholic cirrhosis occurs.
Hepatocellular carcinoma occurs in 5% to 15% of people with alcoholic cirrhosis, but people in whom hepatocellular carcinoma has
developed are often co-infected with hepatitis B or C virus.
Abstinence from alcohol may help people with alcoholic disease in improving their prognosis of survival at any stage of their disease;
however, the more advanced the stage, the higher the risk of complications, co-morbidities, and mortality, and lesser the effect of
abstinence. Being abstinent one month after diagnosis of early cirrhosis will improve the chance of a seven-year life expectancy by 1.6
times. Liver transplantation is the only radical method that may change the prognosis of a person with alcoholic liver disease; however,
besides the difficulties of finding a suitable liver transplant organ, there are many other factors that may influence a person’s survival.
Ultrasound is an inexpensive method that has been used for years in clinical practice to diagnose alcoholic cirrhosis. Ultrasound
parameters for assessing cirrhosis in people with alcoholic liver disease encompass among others liver size, bluntness of the liver edge,
coarseness of the liver parenchyma, nodularity of the liver surface, size of the lymph nodes around the hepatic artery, irregularity and
narrowness of the inferior vena cava, portal vein velocity, and spleen size.
Diagnosis of cirrhosis by ultrasound, especially in people who are asymptomatic, may have its advantages for the prognosis, motivation,
and treatment of these people to decrease their alcohol consumption or become abstinent.
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Timely diagnosis of alcoholic cirrhosis in people with alcoholic liver disease is the cornerstone for evaluation of prognosis or choosing
treatment strategies.
Objectives
To determine the diagnostic accuracy of ultrasonography for detecting the presence or absence of cirrhosis in people with alcoholic
liver disease compared with liver biopsy as reference standard.
To determine the diagnostic accuracy of any of the ultrasonography tests, B-mode or echo-colour Doppler ultrasonography, used singly
or combined, or plus ultrasonography signs, or a combination of these, for detecting hepatic cirrhosis in people with alcoholic liver
disease compared with liver biopsy as a reference standard, irrespective of sequence.
Search methods
We performed searches in The Cochrane Hepato-Biliary Group Controlled Trials Register, The Cochrane Hepato-Biliary Group
Diagnostic Test Accuracy Studies Register, The Cochrane Library (Wiley), MEDLINE (OvidSP), EMBASE (OvidSP), and the Science
Citation Index Expanded to 8 January 2015. We applied no language limitations.
We screened study references of the retrieved studies to identify other potentially relevant studies for inclusion in the review and read
abstract and poster publications.
Selection criteria
Three review authors independently identified studies for possible inclusion in the review. We excluded references not fulfilling the
inclusion criteria of the review protocol. We sent e-mails to study authors.
The included studies had to evaluate ultrasound in the diagnosis of hepatic cirrhosis using only liver biopsy as the reference standard.
The maximum time interval of investigation with liver biopsy and ultrasonography should not have exceeded six months. In addition,
ultrasonography could have been performed before or after liver biopsy.
Data collection and analysis
We followed the Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy.
Main results
The review included two studies that provided numerical data regarding alcoholic cirrhosis in 205 men and women with alcoholic liver
disease. Although there were no applicability concerns in terms of participant selection, index text, and reference standard, we judged
the two studies at high risk of bias. Participants in both studies had undergone both liver biopsy and ultrasonography investigations.
The studies shared only a few comparable clinical signs and symptoms (index tests).
We decided to not perform a meta-analysis due to the high risk of bias and the high degree of heterogeneity of the included studies.
Authors’ conclusions
As the accuracy of ultrasonography in the two included studies was not informative enough, we could not recommend the use of
ultrasonography as a diagnostic tool for liver cirrhosis in people with alcoholic liver disease. In order to be able to answer the review
questions, we need diagnostic ultrasonography prospective studies of adequate sample size, enrolling only participants with alcoholic
liver disease.
The design and report of the studies should follow the Standards for Reporting of Diagnostic Accuracy. The sonographic features, with
validated cut-offs, which may help identify clinical signs used for diagnosis of fibrosis in alcoholic liver disease, should be carefully
selected to achieve maximum diagnostic accuracy on ultrasonography.
P L A I N L A N G U A G E S U M M A R Y
Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease
Background
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Heavy alcohol consumption causes alcoholic liver disease and may lead to a number of other concomitant diseases. Alcohol may damage
the function of body organs and can cause cancer. Liver damage due to excessive alcohol consumption is usually presented as fatty liver
(build-up of fats in the liver), steatohepatitis (inflammation of the liver with concurrent fat accumulation in the liver), fibrosis (fibrous
degeneration), alcoholic cirrhosis (scarring of the liver), and hepatocellular carcinoma (most common type of liver cancer). When liver
fibrosis progresses, alcoholic cirrhosis occurs.
Abstinence from alcohol may help people with alcoholic disease to improve their health at any stage of their disease; however, the more
advanced the stage, the higher the risk of complications, co-morbidities (presence of other diseases), and mortality (death), and lesser
the effect of abstinence. Abstinence from alcohol one month after diagnosis of early cirrhosis will improve the chance of a seven-year
life expectancy by 1.6 times. Liver transplantation (replacement of a diseased liver) is the only radical method that may change the
prognosis of a person with alcoholic liver disease; however, besides the difficulties of finding a suitable liver transplant organ, there are
many other factors that may influence a person’s survival after transplantation.
Ultrasound is an inexpensive method that has been used for years in clinical practice to diagnose alcoholic cirrhosis. Ultrasound
parameters for assessing cirrhosis in people with alcoholic liver disease encompass among others liver size, bluntness of the liver edge,
coarseness of the liver parenchyma (part of the liver that filters blood to remove toxins), nodularity (unevenness) of the liver surface, size
of the lymph nodes (small glands that filter lymph) around the hepatic artery (which supplies oxygenated blood to the liver), irregularity
and narrowness of the inferior vena cava (which carries blood from the lower body to the heart), portal vein velocity, and spleen size.
Diagnosis of cirrhosis by ultrasound, especially in people who have no symptoms, may have its advantages for the prognosis, motivation,
and treatment of these people to decrease their alcohol consumption or become abstinent.
Timely diagnosis of alcoholic cirrhosis in people with alcoholic liver disease is important for evaluation of prognosis or choosing
treatment strategies.
Aim
The primary review aim was to determine the diagnostic accuracy of ultrasound for detecting the presence or absence of cirrhosis in
people with alcoholic liver disease compared with liver biopsy (where a small needle is inserted into the liver to collect a sample, which
is then examined in a laboratory) as reference standard (i.e., the best available test). The secondary aim of the review was to determine
the diagnostic accuracy of any of the ultrasound tests, B-mode (a two-dimensional ultrasound image display composed of bright dots
representing the ultrasound echoes) or echo-colour Doppler ultrasound (a colour ultrasound image showing blood flow through the
liver), used singly or combined, or plus ultrasound signs, or a combination of these, for detecting hepatic cirrhosis in people with
alcoholic liver disease compared with liver biopsy as a reference standard.
Methods
We searched the medical literature to retrieve studies for the review to 8 January 2015.
Results
We identified two studies; one from 1985, performed in France, and the other from 2013, performed in South Korea. We could not
analyse the data as the two studies with 205 participants in total were very different and they shared only a few clinical signs and
symptoms for assessment of cirrhosis. We considered the studies at high risk of bias (the quality of the evidence was low).
Funding
One of the two studies was sponsored by a grant from the Ministry of Health and Welfare, Republic of Korea.
Conclusions
The review authors cannot recommend the use of ultrasound as a diagnostic tool for liver cirrhosis in people with alcoholic liver disease
as the obtained study data were insufficient for analysis. Diagnostic ultrasound prospective studies with a large number of people and
similar signs and features on ultrasound imaging are needed to establish how good the test is in detecting cirrhosis in people with
alcoholic liver disease.
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B A C K G R O U N D
Alcohol consumption is a worldwide problem. Every year approx-
imately 2.5 million people die of it; 320,000 of them are young
people between 15 and 29 years of age. Based on estimates for
2004, alcohol was responsible for almost 4% of all deaths in the
world (WHO 2010).
Heavy alcohol consumption causes alcoholic liver disease and is
a causal factor of many types of liver injuries and concomitant
diseases. It is a true systemic disease that may damage the digestive
tract, the nervous system, the heart and vascular system, the bone
and skeletalmuscle system, and the endocrine and immune system,
and can lead to cancer (WHO 2010; Rocco 2014).
Liver damage in turn, can present as multiple alcoholic liver dis-
eases, including fatty liver, steatohepatitis, fibrosis, alcoholic cir-
rhosis, and hepatocellular carcinoma, with presence or absence of
hepatitis B or C virus infection (Brunt 1974; Bruha 2012; Testino
2014). There are three scarring types (fibrosis) that are most com-
monly found in alcoholic liver disease: centrilobular scarring, peri-
cellular fibrosis, and periportal fibrosis. When liver fibrosis pro-
gresses, alcoholic cirrhosis occurs. Hepatocellular carcinoma oc-
curs in 5% to 15% of people with alcoholic cirrhosis, but people
in whom hepatocellular carcinoma has developed are often co-
infected with hepatitis B or C virus (MacSween 1986; Jaurigue
2014).
Abstinence from alcohol may help people with alcoholic disease
in improving their prognosis of survival at any stage of their dis-
ease; however, the more advanced the stage, the higher the risk of
complications, co-morbidities, and mortality, and lesser the effect
of abstinence (Borowsky 1981). Being abstinent one month after
diagnosis of early cirrhosis will improve the chance of a seven-year
life expectancy by 1.6 times (Verrill 2009). Liver transplantation
is the only radical method that may change the prognosis of a per-
son with alcoholic liver disease; however, besides the difficulties
of finding a suitable liver transplant organ, there are many other
factors that may influence a person’s survival (Iruzubieta 2013;
Singal 2013).
Cochrane systematic reviews of randomised clinical trials of phar-
macological interventions used for reducing alcohol consumption
such as acamprosate, benzodiazepines, naltrexone, gamma-hy-
droxybutyrate, baclofen (derivative of gamma-aminobutyric acid),
and anticonvulsants versus placebo or another drug in alcohol-de-
pendent people have studied the benefits and harms of these inter-
ventions for alcohol reduction or withdrawal (Amato 2010; Leone
2010; Minozzi 2010; Rösner 2010a; Rösner 2010b; Liu 2013;
Pani 2014). However, the conclusions, despite showing some po-
tential tendency of alcohol reduction or promotion of abstinence,
lack the desired robustness of evidence as the performed ran-
domised clinical trials for alcohol withdrawal with the suggested
drug interventions may fail in quality, be of insufficient sample
size, be too heterogeneous, or lack sufficient evidence for benefits.
Without diminishing nutritional and supportive management of
people with alcoholic liver disease, complete abstinence from al-
cohol seems still to be the only recommended form of hepatopro-
tection.
Ultrasound is an inexpensive method that has been used for years
in clinical practice to diagnose alcoholic cirrhosis (Rockey 2009;
O’Shea 2010). Ultrasound parameters for assessing cirrhosis in
people with alcoholic liver disease encompass among others liver
size, bluntness of the liver edge, coarseness of the liver parenchyma,
nodularity of the liver surface, size of the lymph nodes around
the hepatic artery, irregularity and narrowness of the inferior vena
cava, portal vein velocity, and spleen size (Nishiura 2005).
In a series of 1604 people with alcoholic liver disease diagnosed on
liver biopsy or clinically confirmed diagnosis, 608 (38%) people
had developed alcoholic cirrhosis (Naveau 1997). Diagnosis of cir-
rhosis by ultrasound, especially in people who are asymptomatic,
may have its advantages for the prognosis, motivation, and treat-
ment of these people to decrease their alcohol consumption or
become abstinent (O’Shea 2010).
Timely diagnosis of alcoholic cirrhosis in people with alcoholic
liver disease is the cornerstone for evaluation of prognosis or choos-
ing treatment strategies in these people.
Target condition being diagnosed
Cirrhosis in people with alcoholic liver disease
People with alcoholic liver disease are at risk of developing liver
fibrosis and cirrhosis. This risk is considered higher in people who
are binge drinkers, people with increased serum alanine amino-
transferase and aspartate aminotransferase levels, and in people
with severe alcohol hepatitis on liver biopsy (Bouchier 1992). Cir-
rhosis may have symptoms and signs of liver disease, and cirrhosis
may vary from one person to another. In general, people with alco-
holic liver disease see a doctor when symptoms and signs from the
complications of cirrhosis have already developed (O’Shea 2010).
Physicians should attempt tomotivate people to stop drinking. In-
direct evidence of alcohol abuse can be collected through question-
naires about drinking habits, through information received from
family members, and through running laboratory tests (O’Shea
2010).
Hepatic fibrosis may develop as a result of weekly alcohol con-
sumption of seven to 13 beverages for women (one beverage = 12
g of alcohol) and 14 to 27 beverages for men over the course of
five or more years (Savolainen 1993; Becker 1996). The risk ratio
of progression of fibrosis to cirrhosis increases significantly with a
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daily consumption of 20 to 40 g of ethanol in women and more
than 80 g of ethanol in men (Sherlock 1997; O’Shea 2010).
The liver is the main site of alcohol metabolism acting through
two hepatic enzymes, alcohol dehydrogenase and cytochrome P-
450 (CYP) 2E1. Increased alcohol intake disrupts metabolic liver
function, and, as a result, alcoholic liver disease develops (Stewart
2001).
METAVIR is the most widely used scoring system for interpreta-
tion of liver biopsy results based on the stage of fibrosis where F0
indicates no fibrosis, F1 indicates portal fibrous expansion (mild
fibrosis), F2 indicates thin fibrous septa emanating from portal tri-
ads (significant fibrosis), F3 indicates fibrous septa bridging portal
triads and central veins (severe fibrosis), and F4 indicates cirrhosis
(Table 1).
Michalak 2003 validated the reproducibility of the METAVIR
score using a slightly modified METAVIR score, that is, the portal
tract/septal fibrosis score, to investigate the amount of fibrosis and
study the influence of centrilobular fibrosis and portal tract/septal
fibrosis in alcoholic chronic liver disease. The amount of portal
tract/septal fibrosis in people with alcoholic chronic disease was
greater than the amount of centrilobular fibrosis in the control
group of people with viral chronic hepatitis disease, which sug-
gested that portal tract/septal fibrosis was more frequent in alco-
holic chronic liver disease than in viral chronic hepatitis. However,
centrilobular fibrosis forms with the advance of fibrosis in cirrho-
sis. The prognostic value of the METAVIR fibrosis score in alco-
holic liver disease still needs to be established (Michalak 2003).
In Table 1, we have included other widely used systems for classi-
fication of fibrosis in people with alcoholic liver disease (Knodell
1981; Desmet 1994; Ishak 1995; Brunt 1999; Kleiner 2005;
Haque 2010). However, as the focus of our review is on alcoholic
cirrhosis alone, for discrepancies in classification of cirrhosis, we
refer the readers to the last two rows of the table (shaded).
Index test(s)
Ultrasonography is used in clinical practice for diagnosis of cirrho-
sis in people with alcoholic liver disease as it allows investigation
of the hepatic tissue through the generation of ultrasonic waves.
B-mode and Echo-colour Doppler ultrasonography seem to be
the most often used methods for diagnosis of cirrhosis. There are
some other new ultrasound-based methods, such as ultrasound-
based elastography, acoustic radiation force impulse (ARFI), and
supersonic shear imaging.
Ultrasonic patterns obtained at ultrasonography investigation in
B-mode are usually classified as positive or negative considering
signs used in different combinations and defined as indices, for
example, parenchymal (liver surface, volume, edge, and texture),
extrahepatic (spleen volume, presence of ascites), and vascular (di-
ameter of portal and spleen veins). Hepatic fibrosis produces ab-
normal echo patterns on ultrasound scanning. Much higher atten-
uation is observed at examination of the liver of people with steato-
sis compared to the liver of people with hepatic fibrosis (Bamber
1979; Saverymuttu 1986).
Vascular (Doppler) indices, such as Doppler perfusion index, hep-
atic transit time, portal vein congestive index, and various ratios
analysing different blood vessels, are used indirectly for detec-
tion of portal hypertension and cirrhosis (Ersoz 1999; Hizli 2010;
Ivashkin 2011a).
Clinical pathway
Figure 1 presents the clinical pathway in the diagnosis of alcoholic
liver cirrhosis.
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Figure 1. Clinical pathway in the diagnosis of alcoholic liver disease.
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Alternative test(s)
Differentmethods to assess liver fibrosis have been developed since
1990. Most of them are aimed at quantifying the elasticity or
viscoelasticity of the liver tissue. There are two common elements
in every elasticity imaging method: a force or stress is applied on
the liver tissue and the obtained mechanical response is measured.
ARFI (ACUSON S2000; Siemens Ltd.) is a non-invasive imaging
technique that can detect and quantify hepatic fibrosis. The ARFI
technology is also called liver ultrasound elastography (Iyo 2009).
ARFI imaging is faster than conventional methods as ARFI uses
higher frequencies that are comparable to those used in colour
Doppler imaging.The images have greater contrast and the bound-
ary of the focal lesions are better defined compared with conven-
tional ultrasonography imagining techniques (Iyo 2009).
Supersonic shear imaging investigates tissue elasticity to detect
hepatic fibrosis and steatosis. It is based on velocity estimation of
a shear wave, generated by a radiation force (Bercoff 2004).
Magnetic resonance elastography combines magnetic resonance
imaging with sound waves to create a visual map (elastogram)
showing the stiffness of the liver tissue. It is used primarily to detect
hardening of the liver caused by different types of liver diseases,
including those of alcoholic aetiology (Yin 2007).
Transient elastography is another non-invasive method for assess-
ment of hepatic fibrosis (Gómez-Domínguez 2006; Pavlov 2015),
whichmeasures hepatic fibrosis through the stiffness of the hepatic
parenchyma. Transient elastography measures the speed of prop-
agation of the elastic wave through the hepatic parenchyma: the
stiffer the tissue, the faster the shear wave propagates the obtained
hepatic stiffness, expressed as a median value in kiloPascals (kPa).
Other alternative non-invasive tests (apart from venepuncture)
are laboratory tests such as aspartate aminotransferase to ala-
nine aminotransferase ratio, platelet count, prothrombin index,
hyaluronic acid, and enhanced liver fibrosis score (Crespo 2012;
Liu 2012). All of these tests are used as surrogate markers for stag-
ing of hepatic fibrosis. In addition, different combinations of bio-
chemical tests such as FibroTest® and Fibrometre® are used for
diagnosis and staging of hepatic fibrosis in people with alcoholic
liver disease (Morra 2007; Poynard 2007; Poynard 2008; Angulo
2009).
Rationale
Liver biopsy has so far been considered the standard method for
detection of hepatic fibrosis and its staging, using different semi-
quantitativemorphological scores on liver tissue sampleswith a size
of nomore than1 to2 cm3 (Table 1).One advantage of liver biopsy
is that it may give diagnostic information for concurrent liver
diseases (Poulsen 1979; Ismail 2011).However, there are a number
of disadvantages with liver biopsy. It is invasive, and it may have
potential risks to the person such as punctures of abdominal organs
and haemorrhage. Liver biopsy can be painful, time-consuming,
and stressful for the person (Grant 1999; O’Shea 2010; Ivashkin
2011b). The risk of haemorrhage and death after a percutaneous
liver biopsy is especially higher in people with a platelet count of
60,000 per mm3 or less (Seeff 2010). Transjugular liver biopsy
seems a safer alternative for people with low platelet counts or
clotting abnormalities. The small size of the tissue samples, either
obtained transcutaneously or via the transjugular route, may also
lead to sampling errors.
The technical possibilities of the ultrasonography equipment and
the individual experience of the investigator performing the ultra-
sonography are the main factors influencing the precision of the
ultrasound examination. Consensus on using ultrasonography as
a non-invasive method for diagnosis of cirrhosis in people with
alcoholic liver disease seems not to have been established, despite
being widely used instead of, or together with, other non-inva-
sive techniques (Shiha 2009). When a person presents with clini-
cal symptoms (e.g., ascites, encephalopathy, oesophageal bleeding)
of cirrhosis, neither liver biopsy nor ultrasonography are needed.
However, in case of insufficient or unclear expression of clinical
signs, a wait-and-see approach, ultrasonography, or other alterna-
tive non-invasive tests may be considered before arranging a liver
biopsy investigation (Figure 1). As cirrhosis is a main prognostic
variable with impact on survival of people with alcoholic liver dis-
ease, it is important to detect cirrhosis, assess the risk of complica-
tions, and encourage abstinence of drinking alcohol (Leong 2012;
Singal 2013; Testino 2014).
This review aimed to meta-analyse data from studies on the di-
agnosis of cirrhosis in people with alcoholic liver disease and to
assess the diagnostic accuracy of ultrasonography in detecting the
presence of cirrhosis compared with liver biopsy as reference stan-
dard, following Cochrane methodology (SRDTA Handbook).
We did not identify any meta-analysis or systematic review on the
use of ultrasonography for defining the presence of cirrhosis in
people with alcoholic liver disease. A Cochrane systematic diag-
nostic test accuracy review on ultrasonography in detecting cir-
rhosis in people with alcoholic liver disease compared with liver
biopsy does not exist either. Therefore, we conducted this review.
O B J E C T I V E S
To determine the diagnostic accuracy of ultrasonography for de-
tecting the presence or absence of cirrhosis in people with alcoholic
liver disease compared with liver biopsy as reference standard.
Secondary objectives
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To determine the diagnostic accuracy of any of the ultrasonogra-
phy tests, B-mode or Echo-colour Doppler ultrasonography, used
singly or combined, or plus ultrasonography signs, or a combina-
tion of these, for detecting hepatic cirrhosis in people with alco-
holic liver disease compared with liver biopsy as a reference stan-
dard, irrespective of sequence.
In case of discrepancies in the results, we planned to explore het-
erogeneity analysing:
• liver biopsy as the reference standard:
◦ different grade of inflammation (amount of ongoing
inflammation and necrosis) according to the liver biopsy (below
two grades compared to two or greater grades of activity);
◦ different lengths of liver biopsy sample (shorter than
15 mm compared to 15 mm or longer) or number of portal
tracts (fewer than six compared to six or more), as reported in the
studies;
◦ percutaneous liver biopsy versus transvenous
(transjugular) liver biopsy versus laparoscopic liver biopsy;
• different technical characteristics of the ultrasonography
equipment (e.g., different transducers, different wave lengths);
• different skills of the operator as stated by the authors;
• complete abstinent (teetotalers) or non-abstinent study
participants (as defined in the included studies).
In addition, we attempted to identify themost accurate ultrasono-
graphic tests and indices for diagnosis of cirrhosis in people with
alcoholic liver disease.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Diagnostic cohort study designs and diagnostic case-control study
designs that assessed alcoholic cirrhosis in people with alcoholic
liver disease through ultrasonography and liver biopsy, irrespec-
tive of language or publication status, or whether data were col-
lected prospectively or retrospectively.We planned to include ran-
domised clinical trials or controlled clinical studies had they ful-
filled the inclusion criteria of our review protocol.
We included studies published as full paper articles, in the form
of abstracts published in conference proceedings, or presented as
posters if any of these were identified with the searches.
We also considered studies if they had included participants with
different aetiologies of liver disease.
Participants
Participants of any sex and ethnic origin, over 16 years old, and
diagnosed with alcoholic liver disease, following study authors’
statements. The participants could have been hospitalised or man-
aged as outpatients.
The diagnosis of alcoholic liver disease in the study participants
should have been established based on registered history of ex-
cessive alcohol intake of sufficient duration and quantity together
with clinical evidence of liver disease expressed with physical signs
at examination and followed by laboratory evidence of liver dis-
ease. To ascertain the diagnosis of alcoholic liver disease and study
the presence or absence of cirrhosis, both ultrasonography and
liver biopsy should have been performed, irrespective of the se-
quence.
We planned to also include participants if suspected of having
non-alcoholic fatty liver disease, in addition to diagnosed alcoholic
liver disease.
We did not consider for inclusion people diagnosed with alcoholic
liver disease and having a concomitant liver disease such as chronic
hepatitis C virus infection, chronic hepatitis B virus infection, au-
toimmune liver disease, or human immunodeficiency virus (HIV)
infection. We extracted data on study participants with alcoholic
liver disease alone whenever such data were available in the study
report or whenever we could obtain the data required for the re-
view through personal communication with study authors. In the
latter case, we disregarded some of the data presented in the pub-
lication and used the data provided by the study authors through
personal communication.
Index tests
Ultrasonography in any mode.
As we expected that study authors would have used different mea-
surements, signs, and combinations of signs for assessment of cir-
rhosis by ultrasonography with different techniques and mode,
we did not specify these here in advance. However, we considered
parenchymal, vascular, and extrahepatic ultrasonographic signs as
different index tests.
Target conditions
There are five stages of liver fibrosis by METAVIR (Table 1):
• F0 = no fibrosis;
• F1 = mild fibrosis;
• F2 = significant fibrosis;
• F3 = severe fibrosis;
• F4 = cirrhosis.
The target condition is the presence of cirrhosis in people with
alcoholic liver disease, defined using the METAVIR score.
Thus, we dichotomised the fibrosis estimated by the METAVIR
score as follows: we considered people with a METAVIR score of
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F4 as ’diseased’ and people with a METAVIR score of F0 plus F1
plus F2 plus F3 as ’non-diseased’.
Reference standards
Liver biopsy.
Liver biopsy could have been obtained by percutaneous needle
techniques with needles 1.4 to 1.6 mm (16 to 18 gauge) in di-
ameter, transjugular method, or surgical specimens including la-
paroscopy (Kuntz 2008; Ivashkin 2011b).
Liver biopsy is the only existing reference standard for diagnosing
hepatic cirrhosis in people with alcoholic liver disease. Specimens
of liver tissue with a length of at least 15 mm and at least six portal
tracts are among the factors that canprovide reliablemorphological
diagnosis of cirrhosis (Bedossa 2003; Colloredo 2003; Rockey
2009).
If liver biopsy samples were reported with any of the semi-
quantitative scores, that is, METAVIR (Michalak 2003), Kn-
odell (Franciscus 2007), Ishak (Franciscus 2007), Kleiner (Kleiner
2005), Scheuer (Regev 2002), Brunt (Brunt 1999), or Batts-Lud-
wig (Haque 2010), we planned to use a conversion grid for hep-
atic fibrosis staging adapted after Goodman 2007 to only unify
results for hepatic cirrhosis on liver biopsy (Table 1). METAVIR
has already been validated for staging alcoholic cirrhosis (Michalak
2003).
Search methods for identification of studies
We combined electronic searches with reading references of iden-
tified studies of possible interest.
Electronic searches
We searched The Cochrane Hepato-Biliary Group Controlled
Trials Register, The Cochrane Hepato-Biliary Group Diagnos-
tic Test Accuracy Studies Register (hbg.cochrane.org/specialised-
register), The Cochrane Library (Wiley), MEDLINE (OvidSP),
EMBASE (OvidSP), and Science Citation Index EXPANDED
(de Vet 2010). Appendix 1 shows the search strategies with the
time spans of the searches. We applied no language limitations.
Searching other resources
We also screened references of the retrieved studies to identify
other potentially relevant studies for inclusion in our review. We
considered extracting data from studies presented in an abstract
or poster form, or from grey literature only if data for our review
could be found.
Data collection and analysis
We followed the guidelines provided in the Cochrane Handbook
for Systematic Reviews of Diagnostic Test Accuracy.
Selection of studies
Three review authors (CP, MP, and EL) independently identified
studies for possible inclusion in the review. While reading titles or
abstracts, or both, of the identified studies, we excluded references
with a study design not fulfilling the inclusion criteria of our review
protocol. We retrieved the full text of the remaining references.
During this second selection stage, we grouped together multiple
publications of one study fulfilling the inclusion criteria, and then
we screened these publications for complimentary data and we
checked them for discrepancies. Whenever we were in doubt, CP,
GC, or DN wrote e-mails to study authors.
The studies that we included should have evaluated ultrasound
in the diagnosis of hepatic cirrhosis using only liver biopsy as the
reference standard.
The maximum time interval of investigation with liver biopsy
and ultrasonography should not have exceeded six months. In
addition, ultrasonography could have been performed before or
after liver biopsy.
Data extraction and management
Three review authors (CP, GC, and MP) independently extracted
data following the protocol. There were no disagreements between
review authors extracting the data.
The data needed for the conductance of this systematic review
were study origin, year and language of publication, study design,
participants’ epidemiological and laboratory characteristics, defi-
nition of alcoholic liver disease as defined by the authors of the
individual studies considered for inclusion, technical failures in
undertaking liver biopsy and ultrasonography, cirrhosis estimated
by morphological score and ultrasonography, and information re-
lated to the QUADAS-2 items for evaluation of the risk of bias of
the studies (Whiting 2011).
In order to provide data for our analyses, the studies had to provide
data that could help us calculate the true positive, false positive,
true negative, and false negative diagnostic values of ultrasonog-
raphy for diagnosing cirrhosis.
If information on any of the true positive, false positive, true neg-
ative, and false negative diagnostic test values or results were miss-
ing, we contacted the authors of the included studies in order to
obtain missing information. We also contacted authors if other
types of information needed for this review were missing, espe-
cially when the publication was in the form of an abstract or poster
presentation.
We used Excel and Review Manager 5 to add data required for
statistical analyses (RevMan 2014).
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Assessment of methodological quality
Design flaws in test accuracy studies can produce biased results
(Lijmer 1999; Whiting 2004; Rutjes 2006). In addition, evalua-
tion of study results is quite often impossible due to incomplete
reporting (Smidt 2005).
To limit the influence of different biases, four review authors (CP,
GC, MP, and DN), in pairs or independently of one another, as-
sessed the bias risk of the included diagnostic test accuracy studies,
usingQUADAS-2 domains (Whiting 2011). A fifth review author
(ET) was to act as an arbitrator in case of disagreements between
the authors assessing the bias risk of the studies. We contacted
study authors if information on methodology was lacking in order
to assess correctly the risk of bias of the studies.
Appendix 2 shows the adopted items that served the purposes of
our review in addressing the participant spectrum, index test, tar-
get condition, reference standard, and flow and timing, and which
answers also reflect the general quality of the included studies.
We classified studies at low risk of bias if all answers to the signalling
questions of the four domains and applicability were positive. We
classified the studies at high risk of bias if at least one answer to
the signalling questions of the four domains and applicability was
either negative or unclear (Jüni 1999; Whiting 2005).
We used tabular and graphical displays to summarise QUADAS-
2 assessments.
Statistical analysis and data synthesis
We carried out the analyses following Chapter 10 (Analysing and
Presenting Results) of the Cochrane Handbook for Systematic Re-
views of Diagnostic Test Accuracy (Macaskill 2010).We usedReview
Manager 5 software for analyses and plots (RevMan 2014).
When we had assembled the majority of our studies, we planned
to map the individual index tests or index test indices in the indi-
vidual studies and on the basis thereof determine which to select
for meta-analyses. We built two-by-two tables of ultrasonography
performance (true positive, true negative, false positive, false neg-
ative) for each primary study and for each index test (ultrasonog-
raphy mode) and for the pre-defined target condition (cirrhosis).
We estimated sensitivity, specificity, positive and negative likeli-
hood ratios (LR+ and LR-), positive and negative predictive val-
ues (PPV and NPV) with their 95% confidence intervals (CI).
First, we performed a graphical descriptive analysis of the included
studies: we reported forest plots (sensitivity and specificity sepa-
rately, with their 95% CIs) and we planned to provide a graphical
presentation of the studies in the receiver operating characteristic
(ROC) space (sensitivity plotted against 1 - specificity). Second,
we planned to perform a meta-analysis. Where case studies pro-
vided dichotomised data using a common cut-off, we planned to
use the bivariate model and to provide the estimate of the sum-
mary operating point (the point with mean sensitivity and mean
specificity). Otherwise, we intended to use the hierarchical sum-
mary ROC (HSROC) model and to provide a summary ROC
curve (Macaskill 2010). We planned to perform all analyses for
each test separately.
In case of undetermined ultrasonography results, we planned to
follow the intention-to-diagnose approach following which we
intended to add uninterpretable test results as false positive or false
negatives, depending on the liver biopsy result. In this way, we
hoped to avoid potential overestimation of diagnostic test accuracy
of ultrasonography (Schuetz 2012).
We planned to use the pooled estimates obtained from the fitted
models to calculate summary estimates of likelihood ratios. We
intended to assess the probability of ultrasonography to rule in or
to rule out hepatic cirrhosis by considering the estimates of like-
lihood ratios. A high LR+ (usually greater than 10) means that
there is a large increase in post-test probability, starting from pre-
test probability. A low LR- (usually lower than 0.1) means that
there is a large decrease in post-test probability, starting from pre-
test probability (Schoenfeld 1999). Likelihood ratio estimates can
be used in clinical practice to calculate post-test probabilities for
individual people, starting from patient-specific pre-test probabil-
ities.
We planned to perform direct and indirect comparisons between
the index tests by adding co-variates to the bi-variate or HSROC
model (Macaskill 2010). In case of inconsistency of the results
obtained through direct and indirect comparisons, we intended
to report both results; otherwise, we planned to report one of the
results, depending on the availability of comparisons.
One review author (GC) planned to perform all statistical analyses
using SAS statistical software (SAS Institute Inc., Cary,NC,USA).
Investigations of heterogeneity
We did not expect that the ultrasonographic tests and indices used
for diagnosis of cirrhosis in people with alcoholic liver disease
would cause additional heterogeneity to those already mentioned
in Secondary objectives.
Whenever possible, we planned to evaluate the effect of the pre-
specified sources of heterogeneity on the accuracy estimates by
adding some relevant co-variates to the bivariatemodel (Secondary
objectives).
Sensitivity analyses
If possible, depending on number of studies with low risk of bias,
we planned to assess the effect of risk of bias of the included studies
on the diagnostic accuracy by performing a sensitivity analysis,
excluding studies with high or unclear risk of bias, and perform a
separate sensitivity analysis excluding unblinded studies.
We classified a study with high risk of bias if judged as high risk
of bias or unclear risk of bias in at least one of the domains of
QUADAS-2 (Appendix 2).
We also planned to perform a sensitivity analysis of studies with
data received from study authors.
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Assessment of reporting bias
We planned to create a funnel plot to investigate reporting bias
visually, using the statistical method suggested by Deeks et al.
(Deeks 2005).
R E S U L T S
Results of the search
We identified 25,177 references through electronic searches of
The Cochrane Hepato-Biliary Group Controlled Trials Register
(119 references), TheCochrane Hepato-Biliary GroupDiagnostic
Test Accuracy Register (26 references), The Cochrane Library (487
references), MEDLINE (OvidSP) (5927 references), EMBASE
(OvidSP) (14,266), and Science Citation Index Expanded (4352
references). We identified no additional studies by searching other
sources. After exclusion of duplicates, 17,246 references remained.
Having performed two selections, we found that 17,235 were ir-
relevant references. Eleven references seemed to fulfil the inclusion
criteria. However, we had to exclude eight of these references re-
ferring to seven studies, and thus three references describing two
studies remained for inclusion in our review. We extracted data for
the two-by-two tables from two studies; one published as a full-text
article (Richard 1985), and the other provided individual partici-
pant data through personal correspondence, which created a new
reference (Moon 2013). The Richard 1985 study was performed
in France, and the Moon 2013 study was performed in South
Korea and was sponsored by a grant from the Ministry of Health
and Welfare, Republic of Korea. We did not contact the authors
of the French study because of the old year of publication. We
contacted by e-mail two of the study investigators of the Korean
study (KM Moon and SK Baik) (see Notes of the Characteristics
of included studies and Excluded studies) in order to clarify if the
three publications identified shared the same study participants.
As a result, we received incomplete individual participant data on
105/173 participants in an Excel file. The authors expressed their
regret for losing part of the data due to technical problems. This
happened after publication of their article (Moon 2013).
Six of the seven excluded studies (referred to above) could have
been included in our review had it been possible to extract data for
the two-by-two table with the available data (Saverymuttu 1986;
Joseph 1991; Ferral 1992; Gaiani 1997; Aubè 1999; Colli 2003)
(see Characteristics of excluded studies table). We contacted the
authors of three studies (Ferral 1992; Aubè 1999; Colli 2003), and
received two replies (see Excluded studies). We did not contact
authors of two studies as the studies were old (Saverymuttu 1986;
Joseph 1991). The study by Gaiani 1997 included too few partic-
ipants (see Characteristics of excluded studies table). The remain-
ing study was Kim 2013, and through personal communication
with two of the study authors of the Moon 2013 study, we were
told that the Moon 2013 and Kim 2013 studies shared the same
participants.
No studies were awaiting classification.
Figure 2 shows the reference flow.
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Figure 2. Study flow diagram.
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Characteristics of included studies
Wehave summarised the characteristics of the two included studies
in the Characteristics of included studies table.
Study design
The two included studies were prospective cohort single-centre
studies (Richard 1985; Moon 2013) (Characteristics of included
studies table).
Funding
Richard 1985 did not provide any data and Moon 2013 was sup-
ported by a grant from the Korea Healthcare Technology R&
D project, Ministry of Health and Welfare, Republic of Korea
(HI10C2020).
Participants
Richard 1985 included only participants with alcoholic liver dis-
ease, while Moon 2013 included a heterogeneous group of par-
ticipants with alcoholic liver disease, viral hepatitis, and crypto-
genic hepatitis. However, through personal communication, we
obtained individual participant data for only people with alcoholic
liver disease (Moon 2013). No participants were suspected of hav-
ing non-alcoholic fatty liver disease in addition to the alcoholic
liver disease they were diagnosed with. The two studies included
hospitalised participants of both sexes. The participants’ mean age
in Richard 1985 was 55.6 years (57.4 years for men and 53.8 years
for women), and in Moon 2013, the participants’ mean age was
50.5 years (51.1 years for men and 44.0 years for women).
The number of participants with alcoholic liver disease in the two
studies was 205. Richard 1985 included 128 participants with
alcoholic liver disease, out of which 72 had alcoholic cirrhosis on
liver biopsy, andMoon 2013 sent us individual participant data on
105 participants with alcoholic liver disease, and among them, 70
had alcoholic cirrhosis. Therefore, therewere 142participantswith
fibrosis stage F4 (i.e., alcoholic cirrhosis). All of these participants
underwent both the index test (ultrasonography) and the reference
standard (liver biopsy).
The study by Moon 2013 also compared the accuracy of ultra-
sonography versus transient elastography in terms of the degree of
hepatic fibrosis.
Richard 1985 did not sufficiently report the definition of the di-
agnosis of alcoholic liver disease; the study authors wrote that the
included participants had been drinking 80 g of alcohol per day
for no less than one month before hospitalisation. Moon 2013
provided only general characteristics of the participants with cir-
rhosis.
Richard 1985 performed liver biopsy after ultrasonography in 100/
128 participants, but they did not specify the time interval. Moon
2013 performed liver biopsy within one day after ultrasonography
in 105 of the participants following the individual participant data
received by Moon through personal communication.
Liver biopsy morphological scoring systems
Richard 1985 did not describe the morphological scoring systems,
and Moon 2013 used METAVIR fibrosis scoring system (F0 to
F4).
Grade of inflammation
Moon 2013 did not report the level of inflammation. Richard
1985 reported the presence of steatosis in study participants, but
the data reported did not allow us to assess the grade of steatosis
or level of inflammation.
Length of liver biopsy specimen and number of portal tracts
Moon 2013 excluded participants with liver biopsy specimen
lengths less than 15 mm or less than six portal tracts from the
analysis. However, we do not know how many of these excluded
participants had alcoholic cirrhosis. Richard 1985 provided no in-
formation.
Type of liver biopsy
Richard 1985 used laparoscopic liver biopsy in 62 participants and
percutaneous liver biopsy in 38 participants. Moon 2013 did not
report this information.
Study information on the index test - ultrasonography
Richard 1985 evaluated the following eight ultrasonography signs
in combination and each one individually: volume of the liver,
irregular outline, coarse echo patterns, fine bright echo patterns,
attenuation of the ultrasound beam, splenomegaly, ascites, and
portal hypertension. The ultrasonograph used was real-time ultra-
sound equipment with a 3.5 MHz convex probe (Toshiba). One
operator performed one ultrasonography examination per partic-
ipant. They used B-mode ultrasonography.
Moon 2013 developed an ultrasonographic scoring system (USSS)
based on six ultrasonography B-mode and Doppler imaging fea-
tures, used in clinical practice. These features were liver surface
and edge nodularity, parenchyma echogenicity, presence of right
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lobe atrophy, spleen size, splenic vein diameter, and abnormality
of hepatic waveform, to evaluate hepatic cirrhosis. Based on the
evaluation of each of the six features (with values of 0, 1, and 2),
they produced a total score for prediction of liver cirrhosis. The
ultrasonograph used was the Prosound alpha10 (Aloka, Tokyo,
Japan), with a 3.5 MHz convex probe. There was one operator
who performed all ultrasonography examination to determine the
USSS.
Neither study reported follow-up.
The common signs used by Richard 1985 andMoon 2013 were ir-
regular outline (which corresponds to liver surface and edge nodu-
larity in Moon 2013) and splenomegaly (which corresponds to
spleen size in Moon 2013). However, coarse echo patterns, fine
bright echo patterns, and attenuation of the ultrasound beam
are three signs unified in one by Moon 2013 and described as
parenchyma echogenicity. This is why, we present the signs in sep-
arate.
Methodological quality of included studies
Figure 3 and Figure 4 summarise the methodological quality in
the included studies. The overall risk of bias of both Moon 2013
and Richard 1985 was high. However, there were no applicability
concerns.
Figure 3. Risk of bias and applicability concerns graph: review authors’ judgements about each domain
presented as percentages across included studies.
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Figure 4. Risk of bias and applicability concerns summary: review authors’ judgements about each domain
for each included study.
Findings
Two studies that provided numerical data regarding alcoholic cir-
rhosis in men and women with alcoholic liver disease fulfilled the
inclusion criteria of our review. We could use the data of 205
participants for our analysis. Although there were no applicability
concerns in terms of participants selection, index text, and refer-
ence standard, we judged the two studies to be at high risk of bias
(low quality of evidence). Our analyses of the data showed that the
studies shared only a few comparable clinical signs and symptoms,
and the results of the studies were heterogeneous. These were the
reasons not to perform a meta-analysis.
Participants in both studies had undergone both liver biopsy and
ultrasonography investigations. The authors of the two studies
presented their results separately for each ultrasonographic fea-
ture, as well as combined in an overall sensitivity and specificity.
The two studies shared only three of the investigated features (see
Summary of findings). A visual comparison of the sensitivity and
specificity results showed substantial differences. The specificities
obtained by Moon 2013 (from 9% to 31% for six features and
49% overall specificity) were much lower than the obtained speci-
ficities by Richard 1985 (from 29% to 96% for eight features and
79% overall specificity). The same was also observed for the three
common ultrasonography features reported separately as well as
the specificity of the overall ultrasonography results. In general,
the ultrasonographic features investigated byMoon 2013 had low
specificity and higher sensitivity (90% to 100%, overall sensitivity
94%) than by Richard 1985 (from 4% to 81%, overall sensitivity
81%).
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Summary of findings
Review question What is the accuracy of ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic
liver disease?
Population Men and women, over 16 years old, and diagnosed with alcoholic liver disease, following study
authors’ statements
Settings Part icipants could have been hospitalised or managed as outpat ients
Numbers of studies,
participants, and par-
ticipants with the tar-
get disease
2 studies (reported in 3 publicat ions); 205 part icipants contributed with data for the review analysis,
out of which 142 part icipants with the target disease
Study design Prospect ive cohort study design with consecut ive part icipants enrolled
Index tests Ultrasonography (in B-mode and Doppler imaging) signs (singly or combined)
Reference standards Liver biopsy.
Laparoscopic liver biopsy and percutaneous liver biopsy.
Study limitations Studies at high risk of bias. No report of cut-of f values.
Test Studies Participants Sensitivity* (95% CI) Specificity* (95% CI)
* Irregular out line
Liver surface and edge
nodularity
2 205 0.58 (0.46 to 0.70)
0.99 (0.92 to 1.00)
0.86 (0.67 to 0.96)
0.17 (0.07 to 0.34)
* Splenomegaly
Spleen size
2 205 0.43 (0.31 to 0.55)
0.97 (0.90 to 1.00)
0.89 (0.72 to 0.98)
0.23 (0.10 to 0.40)
Attenuat ion of the ultra-
sound beam
1 100 0.58 (0.46 to 0.70) 0.79 (0.59 to 0.92)
Parenchyma
echogenicity
1 105 1.00 (0.95 to 1.00) 0.09 (0.02 to 0.23)
Hepatomegaly 1 100 0.81 (0.70 to 0.89) 0.29 (0.13 to 0.49)
Coarse echo patterns 1 100 0.50 (0.38 to 0.62) 0.86 (0.67 to 0.96)
Fine bright echo pat-
terns
1 100 0.31 (0.20 to 0.43) 0.61 (0.41 to 0.78)
Ascites 1 100 0.38 (0.26 to 0.50) 0.89 (0.72 to 0.98)
Portal hypertension 1 100 0.04 (0.01 to 0.12) 0.96 (0.82 to 1.00)
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Right lobe atrophy 1 105 0.91 (0.82 to 0.97) 0.31 (0.17 to 0.49)
Splenic vein diameter 1 105 0.90 (0.80 to 0.96) 0.09 (0.02 to 0.23)
Hepatic vein waveform 1 105 0.93 (0.84 to 0.98) 0.29 (0.15 to 0.46)
Ultrasound signs com-
bined
1 100 0.81 (0.70 to 0.89) 0.79 (0.59 to 0.92)
Ultrasound sign score 1 105 0.94 (0.86 to 0.98) 0.49 (0.31 to 0.66)
Conclusions: as the accuracy of the listed ultrasonography features in the 2 included studies, singly or as a score, was not
suf f icient ly informative, we cannot recommend the use of ultrasonography as a diagnost ic tool for liver cirrhosis in people
with alcoholic liver disease
CI: conf idence interval.
* Sim ilar tests evaluated by the two studies are presented in one row in the table with their individual sensit ivit ies and
specif icit ies. As we could not perform a meta-analysis due to the risk of bias and heterogeneity, there were no pooled
results.
As one of the studies used combined ultrasound signs (hepatomegaly, irregular out line, coarse echo patterns, f ine bright echo
patterns, attenuat ion of the ultrasound beam, splenomegaly, ascites, portal hypertension) (Richard 1985), and the other study
used them as a score (liver surface and edge nodularity, parenchyma echogenicity, spleen size, right lobe atrophy, splenic
vein diameter, hepat ic vein waveform) (Moon 2013), we presented their individual sensit ivit ies and specif icit ies.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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D I S C U S S I O N
Summary of main results
In this review, we aimed to determine the diagnostic accuracy of
ultrasonography in B-mode or Doppler imaging for detecting the
presence or absence of liver cirrhosis in people with alcoholic liver
disease compared with liver biopsy as reference standard, irrespec-
tive of sequence. We also attempted to determine the diagnos-
tic accuracy of any of the ultrasonography features. We planned
to explore heterogeneity regarding liver biopsy, ultrasonography
equipment and indices used, operator skills, or study participants.
We included two studies that provided numerical data regarding
alcoholic cirrhosis in men and women with alcoholic liver disease.
Our review was based on 205 participants. We judged both of
these studies at high risk of bias due to flow and timing (Richard
1985;Moon 2013), anddue toparticipant selection (Moon 2013).
Participants in both studies had undergone both liver biopsy and
ultrasonography investigations.
Data for ultrasonography were not available for one participant
in Richard 1985 study, but we could not determine how many
participants lacked data on ultrasonography in the Moon 2013
study.
A meta-analysis was not possible due to the very low number of
studies (i.e., two).
Strengths and weaknesses of the review
Despite that we searched the literature systematically for all pub-
lished studies on ultrasonography versus liver biopsy for alcoholic
cirrhosis in people with alcoholic liver disease and that no one else
so far has attempted to systematically collect the evidence on the
use of the ultrasonography technique as a first-line diagnostic tool
following clinical guidelines, we now should consider these points
as weaknesses in title formulation. At the time when we devel-
oped our idea for this review, we built it on the assumption that
liver fibrosis develops differently due to the different aetiological
factors causing the liver injury. Following the research of Verrill
and colleagues, being abstinent from alcohol for one month after
diagnosis of early cirrhosis will improve the chance of a seven-
year life expectancy by 1.6 times in people with alcoholic liver
disease (Verrill 2009). Furthermore, the prevalence of cirrhosis in
heavy drinkers is still not well known. The volume of the liver may
be affected much more during alcohol abuse, and its dimension,
among other ultrasound parameters, would depend on the cause
of the liver disease (Richard 1985; O’Shea 2010; Moon 2013).
However, uniform assessment of the extent of liver damage on ul-
trasonographic image by radiologists is not easy to achieve due to
the subjective assessment of a large number of indices and signs. All
this can affect the diagnostic accuracy of the ultrasound imaging
technique in diagnosing cirrhosis, and this could also have been
an obstacle for study investigators to perform studies assessing the
diagnostic accuracy of ultrasonography using the same or similar
sets of signs and features. Hence, we have chosen to address the
diagnostic test accuracy of ultrasonography in only people with
alcoholic liver disease.
We found only two studies that heterogeneous results and we
could not pool the data. We found a number of studies that at first
selection fulfilled our inclusion criteria, but we could not separate
the data on alcoholic cirrhosis in people with alcoholic liver disease
from the data of cirrhosis that was due to various aetiologies of the
liver disease. We also found other studies that of ultrasonography
for detection of fibrosis, but liver biopsy was not the reference
standard.
The information provided in the studies and through personal
correspondence was not sufficient to fill in lacking knowledge on
whether alcoholic cirrhosis can be identified by using signs or
combinations of signs on ultrasonography.
Applicability of findings to the review question
Despite the relevance of the review question, we could not present
any findings since we only identified two studies.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
As the accuracy of the listed ultrasonography features in the two
included studies, singly or as a score, was not sufficiently informa-
tive, we cannot recommend the use of ultrasonography as a diag-
nostic tool for liver cirrhosis in people with alcoholic liver disease.
Implications for research
In order to answer the review questions, we need diagnostic ultra-
sonography prospective studies of adequate sample size, enrolling
only participants with alcoholic liver disease. The design and re-
port of the studies should follow the Standards for Reporting of
Diagnostic Accuracy (The STARD statement). The sonographic
features, with validated cut-off values, which may help to iden-
tify hepatic signs used for diagnosis of cirrhosis in alcoholic liver
disease should be carefully selected in order to achieve consensus
among radiologists and maximum diagnostic accuracy on ultra-
sonography.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Moon 2013
Study characteristics
Patient sampling Prospective cohort study.
Patient characteristics and set-
ting
Following the published article Moon 2013, 230 participants (187 men, 43 women; aged (mean
± standard deviation) 50.4 ± 9.5 years) with chronic liver disease; 173 with alcoholic liver disease,
and 111 with alcoholic liver cirrhosis
Prospectively measured and analysed: age, sex, height, weight, aetiology of cirrhosis, Child class,
albumin, total bilirubin, prothrombin time, platelet count, liver stiffness measurement by transient
elastography, and 6 ultrasound features (liver surface and edge nodularity, parenchyma echogenicity,
right lobe atrophy, spleen size, splenic vein diameter, and hepatic vein waveform)
All participants were studied using the 2 non-invasive methods: transient elastography (FibroScan;
Echosens, Paris, France) with a 3.5 MHz M probe and ultrasound (Prosound α10; Aloka, Tokyo,
Japan) with a 3.5 MHz convex probe
Hospitalised.
FromOctober 2007 to February 2011, 230 participants admitted to theWonju College ofMedicine
University Hospital with chronic liver disease who underwent liver biopsy were included in this
study
Index tests USSS combining 6 representative sonographic indices in predicting cirrhosis
The USSS produced a combined score for nodularity of the liver surface and edge, parenchyma
echogenicity, presence of right-lobe atrophy, spleen size, splenic vein diameter, and abnormality of
the hepatic vein waveform. The USSS score was evaluated against liver biopsy results
The study authors measured 13 ultrasonography features and the authors analysed each feature
against the degree of hepatic fibrosis. They used a USSS cut-off value of 6 for the diagnosis of overt
cirrhosis, with sensitivity of 89.2% and specificity of 69.4%. Moon 2013 et al. suggested a cut-off
≥ 6 for diagnosis of alcoholic cirrhosis by USSS
Ultrasound (Prosound α10; Aloka, Tokyo, Japan) with a 3.5 MHz convex probe
Target condition and reference
standard(s)
Alcoholic liver cirrhosis (111 participants); liver biopsy (METAVIR scoring system: F0 to F4)
Flow and timing Liver biopsy was performed within 1 day after ultrasonography
Comparative
Notes We received incomplete individual participant data, i.e., on 105/173 participants, by e-mail. The
authors expressed their regret for losing part of the data after publication of their article due to
technical problems (Moon 2013).
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
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Moon 2013 (Continued)
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
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Moon 2013 (Continued)
Richard 1985
Study characteristics
Patient sampling Prospective cohort study design.
Patient characteristics and set-
ting
128 Participants with only alcoholic liver disease; out of these, 72 had morphologically confirmed
cirrhosis
20 people were planned for transjugular biopsy as prothrombin was < 30%, 2 biopsies were not
usable due to bad quality samples, and 6 biopsies showed hepatocellular carcinoma
The participants’ mean age was 55.6 years (57.4 years for men and 53.8 years for women)
Hospitalised.
From 1 March 1983 to 1 April 1984, 128 participants were admitted to Service
d’Hepatogastroenterologie, de Saint-Etienne, Hopital Nord, Cedex, France
Index tests 8 ultrasonography signs such as volume of the liver, irregular outline, coarse echo patterns, fine bright
echo patterns, attenuation of the ultrasound beam, splenomegaly, ascites, and portal hypertension
Used real-time ultrasound equipment with a 3.5 MHz convex probe, Toshiba
Target condition and reference
standard(s)
Hepatic fibrosis or cirrhosis. Liver biopsy (100 participants underwent liver biopsy):
• laparoscopic liver biopsy - 62 participants, and
• percutaneous liver biopsy - 38 participants.
Despite the 2 different methods of obtaining liver tissue sample in the study, there were no data to
prove or disprove difference in their test accuracy
Flow and timing Liver biopsy was performed after ultrasonography in 100/128 participants, but the time interval
was not specified
Comparative
Notes We did not send an e-mail, as the study was from 1985.
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
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Richard 1985 (Continued)
Did the study avoid inappropri-
ate exclusions?
Yes
Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Unclear
Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
USSS: ultrasonographic scoring system.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aubè 1999 No data for alcoholic cirrhosis alone. On 18 June 2014, we requested relevant information for our review from
Paul Calès, the corresponding author of the publication, but received no reply
Colli 2003 No data for alcoholic cirrhosis. On 18 June 2014, we requested relevant information for our review from
Agostino Colli, but he could not access the archived material
Ferral 1992 The provided data for participants with alcoholic cirrhosis could not be used for analysis. Having sent an inquiry
on relevant information for our review to Hector Ferral on 18 June 2014, we received a reply on 3 August
2014; however, the information received could not be used as Hector Ferral, among the other replies provided,
wrote: “We scanned a total of 70 patients who had a liver biopsy. 32 of these patients had liver cirrhosis. 26 of
these patients had cirrhosis either related to viral hepatitis or ethanol abuse. I do not have the precise number
of patients with alcohol induced cirrhosis in this series...”
Gaiani 1997 No data for alcoholic cirrhosis. Too few participants with alcoholic liver disease (6 participants); which is why
we did not contact the authors
Joseph 1991 No data for alcoholic cirrhosis. We did not contact the authors as the study was old
Kim 2013 Participants overlapped with the Moon 2013 study (personal correspondence). Kim 2013 evaluated hepatic
vein arrival time by using microbubble contrast-enhanced ultrasonography. Doppler imaging ultrasonography
was used. Please see the Notes of the included study by Moon 2013 (Characteristics of included studies table).
Saverymuttu 1986 No separate data for people with alcoholic cirrhosis. We did not contact the authors as the study was old. In
addition, the participants for this study were pre-selected for liver biopsy and as the study authors wrote, ...
“these results may not be applicable to abnormal liver ultrasonographic patterns detected on a routine clinical
list.”
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D A T A
Presented below are all the data for all of the tests entered into the review.
Tests. Data tables by test
Test
No. of
studies
No. of
participants
1 Ultrasonography 2 205
2 Irregular outline (liver surface
and edge nodularity)
2 205
3 Splenomegaly (spleen size) 2 205
4 Hepatomegaly 1 100
5 Attenuation of the ultrasound
beam
1 100
6 Parenchyma echogenicity 1 105
7 Coarse echo patterns 1 100
8 Fine bright echo patterns 1 100
9 Ascites 1 100
10 Portal hypertension 1 100
11 Right lobe atrophy 1 105
12 Hepatic vein waveform 1 105
13 Splenic vein diameter 1 105
Test 1. Ultrasonography.
Review: Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease
Test: 1 Ultrasonography
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Moon 2013 66 18 4 17 0.94 [ 0.86, 0.98 ] 0.49 [ 0.31, 0.66 ]
Richard 1985 58 6 14 22 0.81 [ 0.70, 0.89 ] 0.79 [ 0.59, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 2. Irregular outline (liver surface and edge nodularity).
Review: Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease
Test: 2 Irregular outline (liver surface and edge nodularity)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Moon 2013 69 29 1 6 0.99 [ 0.92, 1.00 ] 0.17 [ 0.07, 0.34 ]
Richard 1985 42 4 30 24 0.58 [ 0.46, 0.70 ] 0.86 [ 0.67, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 3. Splenomegaly (spleen size).
Review: Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease
Test: 3 Splenomegaly (spleen size)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Moon 2013 68 27 2 8 0.97 [ 0.90, 1.00 ] 0.23 [ 0.10, 0.40 ]
Richard 1985 31 3 41 25 0.43 [ 0.31, 0.55 ] 0.89 [ 0.72, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 4. Hepatomegaly.
Review: Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease
Test: 4 Hepatomegaly
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Richard 1985 58 20 14 8 0.81 [ 0.70, 0.89 ] 0.29 [ 0.13, 0.49 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 5. Attenuation of the ultrasound beam.
Review: Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease
Test: 5 Attenuation of the ultrasound beam
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Richard 1985 42 6 30 22 0.58 [ 0.46, 0.70 ] 0.79 [ 0.59, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 6. Parenchyma echogenicity.
Review: Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease
Test: 6 Parenchyma echogenicity
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Moon 2013 70 32 0 3 1.00 [ 0.95, 1.00 ] 0.09 [ 0.02, 0.23 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 7. Coarse echo patterns.
Review: Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease
Test: 7 Coarse echo patterns
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Richard 1985 36 4 36 24 0.50 [ 0.38, 0.62 ] 0.86 [ 0.67, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 8. Fine bright echo patterns.
Review: Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease
Test: 8 Fine bright echo patterns
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Richard 1985 22 11 50 17 0.31 [ 0.20, 0.43 ] 0.61 [ 0.41, 0.78 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 9. Ascites.
Review: Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease
Test: 9 Ascites
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Richard 1985 27 3 45 25 0.38 [ 0.26, 0.50 ] 0.89 [ 0.72, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 10. Portal hypertension.
Review: Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease
Test: 10 Portal hypertension
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Richard 1985 3 1 69 27 0.04 [ 0.01, 0.12 ] 0.96 [ 0.82, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 11. Right lobe atrophy.
Review: Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease
Test: 11 Right lobe atrophy
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Moon 2013 64 24 6 11 0.91 [ 0.82, 0.97 ] 0.31 [ 0.17, 0.49 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 12. Hepatic vein waveform.
Review: Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease
Test: 12 Hepatic vein waveform
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Moon 2013 65 25 5 10 0.93 [ 0.84, 0.98 ] 0.29 [ 0.15, 0.46 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 13. Splenic vein diameter.
Review: Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease
Test: 13 Splenic vein diameter
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Moon 2013 63 32 7 3 0.90 [ 0.80, 0.96 ] 0.09 [ 0.02, 0.23 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
A D D I T I O N A L T A B L E S
Table 1. Semi-quantitative histopathological scoring systems for progression of fibrosis to cirrhosis. Conversion grid for the
stages of hepatic fibrosis*
Stage of fibrosis
METAVIR Knodell Ishak Kleiner Desmet Brunt Batts-Ludvig
F0 F0 F0 F0 F0 F0 F0
F1 F1 F1 F1 F1 F1 F1
F1 F1 F2 F1 F1 F1 F1
F2 F3 F3 F2 F2 F2 F2
F3 F3 F4 F2 F3 F3 F3
F4** F4 F5 F3 F4 F4 F4
F4** F4 F6 F4 F4 F4 F4
METAVIR, Knodell, Ishak, Kleiner, Desmet, Brunt, and Batts-Ludvig scoring systems are used to classify fibrosis (and steatosis) due
to alcoholic liver disease. For references, please see review text.
*Adapted from Goodman 2007.
**As the focus of our review is on alcoholic cirrhosis alone, for discrepancies in classification of cirrhosis, we have used the last two rows
of the table (shaded).
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F: stage of hepatic fibrosis. F0: no fibrosis; F1: portal fibrous expansion; F2: thin fibrous septa emanating from portal triads; F3: fibrous
septa bridging portal triads and central veins; F4: cirrhosis. Clinically significant fibrosis is generally defined as F2 or greater on the
METAVIR scale from F0 to F4 with F4 being cirrhosis.
Clinically significant fibrosis is defined as Ishak fibrosis stage F3 to F6, and cirrhosis defined as Ishak fibrosis F5 or F6.
A P P E N D I C E S
Appendix 1. Search strategies
Database Time span Search strategy
Cochrane Hepato-Biliary Group Con-
trolled Trials Register
January 2015. (ultrason* or ultrasound* or echograph* or echotomograph*
or doppler* or B-mode or B-scan or grey*scale) AND ((hepatic
or liver) and (fibrosis or cirrhosis))
Cochrane Hepato-Biliary Group Diagnos-
tic Test of Accuracy Studies Register
January 2015. (ultrason* or ultrasound* or echograph* or echotomograph*
or doppler* or B-mode or B-scan or grey*scale) AND ((hepatic
or liver) and (fibrosis or cirrhosis))
The Cochrane Library Issue 12 of 12, 2014. #1 MeSH descriptor: [Ultrasonography] explode all trees
#2 (ultrason* or ultrasound* or echograph* or echotomo-
graph* or doppler* or B-mode or B-scan or grey*scale)
#3 #1 or #2
#4 MeSH descriptor: [Liver Cirrhosis] this term only
#5 ((hepatic or liver) and (fibrosis or cirrhosis))
#6 #4 or #5
#7 #3 and #6
MEDLINE (OvidSP) 1946 to January 2015. 1. exp Ultrasonography/
2. (ultrason* or ultrasound* or echograph* or echotomograph*
or doppler* or B-mode or B-scan or grey*scale).mp. [mp=ti-
tle, abstract, original title, name of substance word, subject
heading word, keyword heading word, protocol supplemen-
tary concept word, rare disease supplementary concept word,
unique identifier]
3. 1 or 2
4. exp Liver Cirrhosis/
5. ((hepatic or liver) and (fibrosis or cirrhosis)).mp. [mp=ti-
tle, abstract, original title, name of substance word, subject
heading word, keyword heading word, protocol supplemen-
tary concept word, rare disease supplementary concept word,
unique identifier]
6. 4 or 5
7. 3 and 6
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(Continued)
EMBASE (OvidSP) 1974 to January 2015. 1. exp echography/
2. (ultrason* or ultrasound* or echograph* or echotomograph*
or doppler* or B-mode or B-scan or grey*scale).mp. [mp=title,
abstract, subject headings, heading word, drug trade name,
original title, device manufacturer, drug manufacturer, device
trade name, keyword]
3. 1 or 2
4. exp liver cirrhosis/
5. exp liver fibrosis/
6. ((hepatic or liver) and (fibrosis or cirrhosis)).mp. [mp=title,
abstract, subject headings, heading word, drug trade name,
original title, device manufacturer, drug manufacturer, device
trade name, keyword]
7. 4 or 5 or 6
8. 3 and 7
Science Citation Index Expanded 1900 to January 2015. #3 #2 AND #1
#2 TS=((hepatic or liver) and (fibrosis or cirrhosis))
#1 TS=(ultrason* or ultrasound* or echograph* or echotomo-
graph* or doppler* or B-mode or B-scan or grey*scale)
Appendix 2. QUADAS-2
Domain Participant selection Index test Reference standard Flow and timing
Description Describe methods of
participant selection:
describe included par-
ticipants (prior testing,
presentation, intended
use of index test, and
setting):
The studies that fulfil
the inclusion criteria of
this review should have
included participants of
any sex and ethnic ori-
gin, > 16 years old, and
diagnosed with alcoholic
liver disease. The partic-
ipants could have been
hospitalised or managed
as outpatients. The di-
agnosis of alcoholic liver
Describe the index test
and how it was con-
ducted and interpreted:
Ultrasonography for di-
agnosing cirrhosis, con-
ducted before or after
liver biopsy
Describe the reference
standard and how it
was conducted and in-
terpreted:
Liver biopsy with ≥ 6
portal tracts or length of
liver biopsy specimen >
15 mm was considered
adequate in establishing
cirrhosis in people with
alcoholic liver disease
The morpho-
logical interpretation of
the liver biopsy samples
was reported with semi-
quantitative scores such
as METAVIR, Knodell,
Ishak, Kleiner, Scheuer,
Describe any people
who did not receive the
index test(s) or refer-
ence standard (or both)
or who were excluded
from the 2 x 2 table
(refer to flow diagram)
: describe the time in-
terval and any inter-
ventions between in-
dex test(s) and refer-
ence standard:
As early cirrhosis may
reverse with time in
abstinent people, but
mild to moderate fibro-
sis may evolve to cirrho-
sis in non-abstinent peo-
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(Continued)
disease had to be estab-
lished based on regis-
tered history of excessive
alcohol intake of suffi-
cient duration and quan-
tity together with clini-
cal evidence of liver dis-
ease expressedwith phys-
ical signs at examina-
tion and followed by
laboratory evidence of
liver disease. We ex-
cluded other causes of
liver disease such as vi-
ral hepatitis, autoimmu-
nity, metabolic diseases,
and toxins. To ascertain
the diagnosis of alcoholic
liver disease and study
the presence of cirrho-
sis, both ultrasonogra-
phy and liver biopsy had
to be performed, irre-
spective of the sequence
Brunt, or and Batts-Lud-
vig (see Table 1)
ple, we excluded partici-
pants if the time interval
between diagnostic liver
biopsy and ultrasonogra-
phy investigations was >
6 months
Signalling questions:
yes/no/unclear
Was a consecutive or
random sample of par-
ticipants enrolled?
Yes: all consecutive par-
ticipants or random sam-
ple of people with diag-
nosed alcoholic liver dis-
ease were enrolled in the
study
No: selected participants
were not included.
Unclear: insuffi-
cient data were reported
to permit a judgement
Were the index test re-
sults interpreted with-
out knowledge of the
results of the reference
standard?
Yes: ultrasonography test
results were interpreted
without knowledge of
the results of the liver
biopsy
No: ultrasonography re-
sults were interpreted
with knowledge of the
results of the liver biopsy
Unclear: insuffi-
cient data were reported
to permit a judgement
Is the reference stan-
dard likely to clas-
sify the target condi-
tion correctly?
Yes: if participants have
undergone liver biopsy
and the liver tissue spec-
imen was deemed ade-
quate for confident his-
tological assessment
No: the liver tissue speci-
men was not deemed ad-
equate for confident his-
tological assessment
Unclear: insuffi-
cient data were reported
to permit a judgement
Was there an appropri-
ate interval between in-
dex test(s) and refer-
ence standard?
Yes: the interval between
the ultrasonography and
liver biopsy was ≤ 6
months
No: the interval between
the ultrasonography test
and liver biopsy was > 6
months
Unclear: insuffi-
cient data were reported
to permit a judgement
Was a patient-control
design avoided?
Yes: patient-control de-
sign was avoided.
No: patient-control de-
sign was not avoided.
If a threshold was used,
was it pre-specified?
Yes.
No.
Unclear: it is not re-
ported or not clearly de-
Were the reference
standard results inter-
preted without knowl-
edge of the results of
the index test?
Yes: liver biopsy results
Did all participants re-
ceive the reference stan-
dard?
Yes: all participants un-
derwent the reference
standard, liver biopsy
37Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Unclear: insufficient in-
formation was reported
to permit a judgement
scribed. were interpreted without
knowledge of the results
of the ultrasonography
test
No: liver biopsy results
were interpretedwith the
knowledge of the results
of the ultrasonography
test
Unclear: insuffi-
cient data were reported
to permit a judgement
No: not all participants
underwent liver biopsy.
Unclear: insuffi-
cient data were reported
to permit a judgement
Did the study avoid in-
appropriate
exclusions?
Yes: the study avoided
inappropriate exclusions
(e.g., difficult to diag-
nose participants, failure
at liver biopsy, failure on
ultrasonography)
No: the study excluded
participants inappropri-
ately.
Unclear: insuffi-
cient data were reported
to permit a judgement
Did all participants re-
ceive the same reference
standard?
Yes: all participants re-
ceived the same refer-
ence standard (i.e., liver
biopsy)
No: not all participants
received the same refer-
ence standard (i.e., liver
biopsy)
Unclear: insuffi-
cient data were reported
to permit a judgement
Were all participants
included in the analy-
sis?
Yes:
all participants meeting
the selection criteria (se-
lected participants) were
included in the analysis,
or data on all the se-
lected participants were
available so that a 2 x
2 table including all se-
lected participants could
be constructed
No: not all participants
meeting the selection cri-
teriawere included in the
analysis or the 2 x 2 table
could not be constructed
using data on all selected
participants
Unclear: insuffi-
cient data were reported
to permit a judgement
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(Continued)
Risk of bias: high/low/
unclear
Could the selection of
participants have intro-
duced bias?
High risk of bias: yes, if
the selection of partici-
pants could have intro-
duced bias
Low risk of bias: no, if
the selection of partici-
pants could not have in-
troduced bias
Unclear risk of bias: in-
sufficient data on partic-
ipant selection were re-
ported to permit a judge-
ment on the risk of bias
Could the conduct or
interpretation of the
index test have intro-
duced bias?
High risk of bias: if the
answer to the signalling
questions on the conduct
or interpretation of the
index test was ’no’
Low risk of bias: if the
answer to the signalling
questions on the conduct
or interpretation of the
index test was ’yes’
Unclear risk of bias: if
the answers to the 2
signalling questions on
the conduct or interpre-
tation of the index test
was either ’unclear’ or
any combination of ’un-
clear’ with ’yes’ or ’no’
Could
the reference standard,
its conduct, or its in-
terpretation have intro-
duced bias?
High risk of bias: if the
answer to the signalling
questions on the refer-
ence standard, its con-
duct, or its interpreta-
tion was ’no’
Low risk of bias: if the
answer to the signalling
questions on the refer-
ence standard, its con-
duct, or its interpreta-
tion was ’yes’
Unclear risk of bias: if
the answers to the 3
signalling questions on
the reference standard,
its conduct, or its in-
terpretation was either
’unclear’ or any combi-
nation of ’unclear’ with
’yes’ or ’no’
Could the participant
flow have introduced
bias?
High risk of bias: if the
answer to the signalling
questions on flow and
timing was ’no’
Low risk of bias: if the
answer to the signalling
questions on flow and
timing was ’yes’
Unclear risk of bias: if
the answers to the 4 sig-
nalling questions on flow
and timing was either
’unclear’ or any combi-
nation of ’unclear’ with
’yes’ or ’no’
Concerns regard-
ing applicability: high/
low/unclear
Are there concerns that
the included partici-
pants do not match the
review question?
High concern: there was
high concern that the in-
cluded participants did
not match the review
question
Low concern: there was
low concern that the in-
cluded participants did
not match the review
question
Unclear concern: if it was
unclear.
Are there concerns that
the index test, its con-
duct, or interpretation
differed from the re-
view question?
High concern: there was
high concern that the
conduct or interpreta-
tion of the ultrasonog-
raphy test differed from
theway it was likely to be
used in clinical practice
Low concern: there was
low concern that the
conduct or interpreta-
tion of the ultrasonog-
raphy test differed from
theway it was likely to be
used in clinical practice
Unclear concern: if it was
unclear.
Are there concerns that
the target condition as
defined by the refer-
ence standard does not
match the review ques-
tion?
High concern: all partic-
ipants did not undergo
liver biopsy for cirrhosis
Low concern: all partic-
ipants underwent liver
biopsy for cirrhosis
Unclear concern: if it is
unclear.
-
39Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C O N T R I B U T I O N S O F A U T H O R S
Chavdar Pavlov: selected studies for inclusion or exclusion, extracted data, performedmethodological evaluation of the included studies,
wrote to study authors, drafted and revised the review, and is guarantor of the review.
Giovanni Casazza: selected studies for inclusion or exclusion, extracted data, performed methodological evaluation of the included
studies, wrote e-mails to study authors, performed statistical analysis, and drafted and revised the review.
Marianna Semenistaia (earlier Pavlova): revised the review.
Dimitrinka Nikolova: wrote e-mails to study authors and revised the review.
Emmanuel Tsochatzis: commented on the review.
Ekaterina Lusina: commented on the review.
Vladimir T Ivashkin: commented on the review.
Christian Gluud: commented and revised the review.
All review authors agreed on the final version of the review.
D E C L A R A T I O N S O F I N T E R E S T
Chavdar Pavlov: none known.
Giovanni Casazza: none known.
Marianna Semenistaya (earlier Pavlova): none known.
Dimitrinka Nikolova: none known.
Emmanuel Tsochatzis: none known.
Ekaterina Lusina: none known.
Vladimir T Ivashkin: none known.
Christian Gluud: none known.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• The Editorial Team Office, The Cochrane Hepato-Biliary Group, Copenhagen, Denmark, Denmark.
40Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We have added ’alcoholic’ to cirrhosis for precision of expression.
Marianna Pavlova (author of the protocol) is the same person as Marianna Semenistaya (author of the review).
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